nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR1—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00423	0.00423	CbGpPWpGaD
Ponatinib—PDGFRA—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00422	0.00422	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by ERBB4—TSC2—vascular cancer	0.00418	0.00418	CbGpPWpGaD
Ponatinib—FGFR1—IRS-related events—TSC2—vascular cancer	0.00415	0.00415	CbGpPWpGaD
Ponatinib—FGFR1—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.00411	0.00411	CbGpPWpGaD
Ponatinib—FGFR2—PI-3K cascade—TSC2—vascular cancer	0.00408	0.00408	CbGpPWpGaD
Ponatinib—KIT—PI-3K cascade—TSC2—vascular cancer	0.00401	0.00401	CbGpPWpGaD
Ponatinib—FGFR1—Insulin receptor signalling cascade—TSC2—vascular cancer	0.004	0.004	CbGpPWpGaD
Ponatinib—FGFR1—IGF1R signaling cascade—TSC2—vascular cancer	0.004	0.004	CbGpPWpGaD
Ponatinib—FGFR3—Downstream signal transduction—TSC2—vascular cancer	0.00399	0.00399	CbGpPWpGaD
Ponatinib—FGFR2—PI3K/AKT activation—TSC2—vascular cancer	0.00399	0.00399	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by FGFR—TSC2—vascular cancer	0.00397	0.00397	CbGpPWpGaD
Ponatinib—FGFR2—GAB1 signalosome—TSC2—vascular cancer	0.00396	0.00396	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by ERBB2—TSC2—vascular cancer	0.00395	0.00395	CbGpPWpGaD
Ponatinib—FGFR3—DAP12 signaling—TSC2—vascular cancer	0.00393	0.00393	CbGpPWpGaD
Ponatinib—KIT—PI3K/AKT activation—TSC2—vascular cancer	0.00392	0.00392	CbGpPWpGaD
Ponatinib—KIT—GAB1 signalosome—TSC2—vascular cancer	0.00388	0.00388	CbGpPWpGaD
Ponatinib—FGFR3—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00388	0.00388	CbGpPWpGaD
Ponatinib—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00386	0.00386	CbGpPWpGaD
Ponatinib—FGFR1—PI-3K cascade—TSC2—vascular cancer	0.00381	0.00381	CbGpPWpGaD
Ponatinib—PDGFRA—PI-3K cascade—TSC2—vascular cancer	0.0038	0.0038	CbGpPWpGaD
Ponatinib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.0038	0.0038	CbGpPWpGaD
Ponatinib—FGFR1—PI3K/AKT activation—TSC2—vascular cancer	0.00372	0.00372	CbGpPWpGaD
Ponatinib—PDGFRA—PI3K/AKT activation—TSC2—vascular cancer	0.00371	0.00371	CbGpPWpGaD
Ponatinib—FGFR3—DAP12 interactions—TSC2—vascular cancer	0.0037	0.0037	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by FGFR in disease—TSC2—vascular cancer	0.0037	0.0037	CbGpPWpGaD
Ponatinib—FGFR3—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.0037	0.0037	CbGpPWpGaD
Ponatinib—FGFR1—GAB1 signalosome—TSC2—vascular cancer	0.00369	0.00369	CbGpPWpGaD
Ponatinib—PDGFRA—GAB1 signalosome—TSC2—vascular cancer	0.00368	0.00368	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by EGFR—TSC2—vascular cancer	0.00367	0.00367	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00363	0.00363	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by PDGF—TSC2—vascular cancer	0.00362	0.00362	CbGpPWpGaD
Ponatinib—FGFR1—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.0036	0.0036	CbGpPWpGaD
Ponatinib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00359	0.00359	CbGpPWpGaD
Ponatinib—FGFR4—Disease—WWTR1—vascular cancer	0.00357	0.00357	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by Insulin receptor—TSC2—vascular cancer	0.00357	0.00357	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—WWTR1—vascular cancer	0.00355	0.00355	CbGpPWpGaD
Ponatinib—FGFR3—B Cell Activation—TSC2—vascular cancer	0.00342	0.00342	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by NGF—TSC2—vascular cancer	0.00341	0.00341	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	0.00337	0.00337	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by Insulin receptor—TSC2—vascular cancer	0.00333	0.00333	CbGpPWpGaD
Ponatinib—FGFR3—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00328	0.00328	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—CD34—vascular cancer	0.00319	0.00319	CbGpPWpGaD
Ponatinib—LYN—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00317	0.00317	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by SCF-KIT—TSC2—vascular cancer	0.00305	0.00305	CbGpPWpGaD
Ponatinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00305	0.00305	CbGpPWpGaD
Ponatinib—KIT—Signaling by SCF-KIT—TSC2—vascular cancer	0.003	0.003	CbGpPWpGaD
Ponatinib—FGFR2—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00292	0.00292	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by ERBB4—TSC2—vascular cancer	0.00287	0.00287	CbGpPWpGaD
Ponatinib—KIT—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00287	0.00287	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by SCF-KIT—TSC2—vascular cancer	0.00285	0.00285	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by SCF-KIT—TSC2—vascular cancer	0.00284	0.00284	CbGpPWpGaD
Ponatinib—KIT—Signaling by ERBB4—TSC2—vascular cancer	0.00282	0.00282	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.0028	0.0028	CbGpPWpGaD
Ponatinib—FGFR2—Downstream signal transduction—TSC2—vascular cancer	0.00275	0.00275	CbGpPWpGaD
Ponatinib—LCK—PI-3K cascade—TSC2—vascular cancer	0.00275	0.00275	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by FGFR—TSC2—vascular cancer	0.00273	0.00273	CbGpPWpGaD
Ponatinib—FGFR1—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00272	0.00272	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by ERBB2—TSC2—vascular cancer	0.00272	0.00272	CbGpPWpGaD
Ponatinib—PDGFRA—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00272	0.00272	CbGpPWpGaD
Ponatinib—FGFR2—DAP12 signaling—TSC2—vascular cancer	0.00271	0.00271	CbGpPWpGaD
Ponatinib—KIT—Downstream signal transduction—TSC2—vascular cancer	0.0027	0.0027	CbGpPWpGaD
Ponatinib—KIT—Signaling by FGFR—TSC2—vascular cancer	0.00268	0.00268	CbGpPWpGaD
Ponatinib—LCK—PI3K/AKT activation—TSC2—vascular cancer	0.00268	0.00268	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by ERBB4—TSC2—vascular cancer	0.00268	0.00268	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by ERBB4—TSC2—vascular cancer	0.00267	0.00267	CbGpPWpGaD
Ponatinib—KIT—Signaling by ERBB2—TSC2—vascular cancer	0.00267	0.00267	CbGpPWpGaD
Ponatinib—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00267	0.00267	CbGpPWpGaD
Ponatinib—LCK—GAB1 signalosome—TSC2—vascular cancer	0.00266	0.00266	CbGpPWpGaD
Ponatinib—KIT—DAP12 signaling—TSC2—vascular cancer	0.00266	0.00266	CbGpPWpGaD
Ponatinib—FGFR3—Disease—WWTR1—vascular cancer	0.00264	0.00264	CbGpPWpGaD
Ponatinib—KIT—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00262	0.00262	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—CD34—vascular cancer	0.00261	0.00261	CbGpPWpGaD
Ponatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.0026	0.0026	CbGpPWpGaD
Ponatinib—FGFR1—Downstream signal transduction—TSC2—vascular cancer	0.00256	0.00256	CbGpPWpGaD
Ponatinib—PDGFRA—Downstream signal transduction—TSC2—vascular cancer	0.00255	0.00255	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by FGFR—TSC2—vascular cancer	0.00255	0.00255	CbGpPWpGaD
Ponatinib—FGFR2—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00255	0.00255	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by FGFR in disease—TSC2—vascular cancer	0.00255	0.00255	CbGpPWpGaD
Ponatinib—FGFR2—DAP12 interactions—TSC2—vascular cancer	0.00255	0.00255	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by FGFR—TSC2—vascular cancer	0.00254	0.00254	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by ERBB2—TSC2—vascular cancer	0.00253	0.00253	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by ERBB2—TSC2—vascular cancer	0.00253	0.00253	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by EGFR—TSC2—vascular cancer	0.00252	0.00252	CbGpPWpGaD
Ponatinib—FGFR1—DAP12 signaling—TSC2—vascular cancer	0.00252	0.00252	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by NGF—TSC2—vascular cancer	0.00252	0.00252	CbGpPWpGaD
Ponatinib—PDGFRA—DAP12 signaling—TSC2—vascular cancer	0.00252	0.00252	CbGpPWpGaD
Ponatinib—LYN—Signaling by SCF-KIT—TSC2—vascular cancer	0.0025	0.0025	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—WWTR1—vascular cancer	0.0025	0.0025	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.0025	0.0025	CbGpPWpGaD
Ponatinib—KIT—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.0025	0.0025	CbGpPWpGaD
Ponatinib—KIT—DAP12 interactions—TSC2—vascular cancer	0.0025	0.0025	CbGpPWpGaD
Ponatinib—KIT—Signaling by FGFR in disease—TSC2—vascular cancer	0.0025	0.0025	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by PDGF—TSC2—vascular cancer	0.00249	0.00249	CbGpPWpGaD
Ponatinib—FGFR1—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00249	0.00249	CbGpPWpGaD
Ponatinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00248	0.00248	CbGpPWpGaD
Ponatinib—KIT—Signaling by EGFR—TSC2—vascular cancer	0.00248	0.00248	CbGpPWpGaD
Ponatinib—KIT—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00246	0.00246	CbGpPWpGaD
Ponatinib—KIT—Signaling by PDGF—TSC2—vascular cancer	0.00244	0.00244	CbGpPWpGaD
Ponatinib—FGFR1—DAP12 interactions—TSC2—vascular cancer	0.00237	0.00237	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by FGFR in disease—TSC2—vascular cancer	0.00237	0.00237	CbGpPWpGaD
Ponatinib—FGFR1—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00237	0.00237	CbGpPWpGaD
Ponatinib—PDGFRA—DAP12 interactions—TSC2—vascular cancer	0.00237	0.00237	CbGpPWpGaD
Ponatinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00237	0.00237	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by FGFR in disease—TSC2—vascular cancer	0.00237	0.00237	CbGpPWpGaD
Ponatinib—ABL1—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00236	0.00236	CbGpPWpGaD
Ponatinib—FGFR2—B Cell Activation—TSC2—vascular cancer	0.00236	0.00236	CbGpPWpGaD
Ponatinib—SRC—GAB1 signalosome—TSC2—vascular cancer	0.00235	0.00235	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by EGFR—TSC2—vascular cancer	0.00235	0.00235	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by EGFR—TSC2—vascular cancer	0.00234	0.00234	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00233	0.00233	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00232	0.00232	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by PDGF—TSC2—vascular cancer	0.00232	0.00232	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by PDGF—TSC2—vascular cancer	0.00231	0.00231	CbGpPWpGaD
Ponatinib—KIT—B Cell Activation—TSC2—vascular cancer	0.00231	0.00231	CbGpPWpGaD
Ponatinib—FGFR2—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00225	0.00225	CbGpPWpGaD
Ponatinib—KIT—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00221	0.00221	CbGpPWpGaD
Ponatinib—FGFR1—B Cell Activation—TSC2—vascular cancer	0.0022	0.0022	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—CD34—vascular cancer	0.00219	0.00219	CbGpPWpGaD
Ponatinib—PDGFRA—B Cell Activation—TSC2—vascular cancer	0.00219	0.00219	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—CD34—vascular cancer	0.00215	0.00215	CbGpPWpGaD
Ponatinib—FGFR1—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.0021	0.0021	CbGpPWpGaD
Ponatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.0021	0.0021	CbGpPWpGaD
Ponatinib—LYN—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00209	0.00209	CbGpPWpGaD
Ponatinib—LCK—Signaling by SCF-KIT—TSC2—vascular cancer	0.00205	0.00205	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—CD34—vascular cancer	0.00204	0.00204	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—CD34—vascular cancer	0.00204	0.00204	CbGpPWpGaD
Ponatinib—LCK—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00196	0.00196	CbGpPWpGaD
Ponatinib—FGFR4—Innate Immune System—TSC2—vascular cancer	0.00194	0.00194	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—CD34—vascular cancer	0.00193	0.00193	CbGpPWpGaD
Ponatinib—LCK—Signaling by ERBB4—TSC2—vascular cancer	0.00193	0.00193	CbGpPWpGaD
Ponatinib—LYN—B Cell Activation—TSC2—vascular cancer	0.00193	0.00193	CbGpPWpGaD
Ponatinib—FGFR4—Adaptive Immune System—TSC2—vascular cancer	0.00187	0.00187	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—WWTR1—vascular cancer	0.00185	0.00185	CbGpPWpGaD
Ponatinib—LCK—Downstream signal transduction—TSC2—vascular cancer	0.00185	0.00185	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR—TSC2—vascular cancer	0.00184	0.00184	CbGpPWpGaD
Ponatinib—LCK—Signaling by ERBB2—TSC2—vascular cancer	0.00183	0.00183	CbGpPWpGaD
Ponatinib—LCK—DAP12 signaling—TSC2—vascular cancer	0.00182	0.00182	CbGpPWpGaD
Ponatinib—FGFR2—Disease—WWTR1—vascular cancer	0.00182	0.00182	CbGpPWpGaD
Ponatinib—SRC—Signaling by SCF-KIT—TSC2—vascular cancer	0.00182	0.00182	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—CD34—vascular cancer	0.0018	0.0018	CbGpPWpGaD
Ponatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00179	0.00179	CbGpPWpGaD
Ponatinib—SRC—BDNF signaling pathway—TSC2—vascular cancer	0.00179	0.00179	CbGpPWpGaD
Ponatinib—KIT—Disease—WWTR1—vascular cancer	0.00179	0.00179	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by NGF—TSC2—vascular cancer	0.00173	0.00173	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR in disease—TSC2—vascular cancer	0.00171	0.00171	CbGpPWpGaD
Ponatinib—LCK—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00171	0.00171	CbGpPWpGaD
Ponatinib—LCK—DAP12 interactions—TSC2—vascular cancer	0.00171	0.00171	CbGpPWpGaD
Ponatinib—KIT—Signaling by NGF—TSC2—vascular cancer	0.0017	0.0017	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR—TSC2—vascular cancer	0.0017	0.0017	CbGpPWpGaD
Ponatinib—FGFR1—Disease—WWTR1—vascular cancer	0.00169	0.00169	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—WWTR1—vascular cancer	0.00169	0.00169	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00168	0.00168	CbGpPWpGaD
Ponatinib—LCK—Signaling by PDGF—TSC2—vascular cancer	0.00167	0.00167	CbGpPWpGaD
Ponatinib—SRC—Downstream signal transduction—TSC2—vascular cancer	0.00163	0.00163	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR—TSC2—vascular cancer	0.00163	0.00163	CbGpPWpGaD
Ponatinib—SRC—Signaling by ERBB2—TSC2—vascular cancer	0.00162	0.00162	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—TSC2—vascular cancer	0.00162	0.00162	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—WWTR1—vascular cancer	0.00161	0.00161	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by NGF—TSC2—vascular cancer	0.00161	0.00161	CbGpPWpGaD
Ponatinib—LCK—B Cell Activation—TSC2—vascular cancer	0.00158	0.00158	CbGpPWpGaD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00152	0.00152	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—TSC2—vascular cancer	0.00151	0.00151	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR—TSC2—vascular cancer	0.0015	0.0015	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—WWTR1—vascular cancer	0.0015	0.0015	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00149	0.00149	CbGpPWpGaD
Ponatinib—BCR—Disease—TSC2—vascular cancer	0.00148	0.00148	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—TSC2—vascular cancer	0.00148	0.00148	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD34—vascular cancer	0.00147	0.00147	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—TSC2—vascular cancer	0.00144	0.00144	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	0.00138	0.00138	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—TSC2—vascular cancer	0.00138	0.00138	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00134	0.00134	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD34—vascular cancer	0.00133	0.00133	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD34—vascular cancer	0.00131	0.00131	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD34—vascular cancer	0.0013	0.0013	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—WWTR1—vascular cancer	0.00127	0.00127	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—WWTR1—vascular cancer	0.00125	0.00125	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD34—vascular cancer	0.00124	0.00124	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD34—vascular cancer	0.00124	0.00124	CbGpPWpGaD
Ponatinib—LCK—Disease—WWTR1—vascular cancer	0.00122	0.00122	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—WWTR1—vascular cancer	0.00119	0.00119	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—WWTR1—vascular cancer	0.00118	0.00118	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—TSC2—vascular cancer	0.00117	0.00117	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—TSC2—vascular cancer	0.00113	0.00113	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD34—vascular cancer	0.00109	0.00109	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD34—vascular cancer	0.00109	0.00109	CbGpPWpGaD
Ponatinib—SRC—Disease—WWTR1—vascular cancer	0.00108	0.00108	CbGpPWpGaD
Ponatinib—FGFR4—Disease—TSC2—vascular cancer	0.00105	0.00105	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—WWTR1—vascular cancer	0.00104	0.00104	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TSC2—vascular cancer	0.00104	0.00104	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—TSC2—vascular cancer	0.00103	0.00103	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—WWTR1—vascular cancer	0.000991	0.000991	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—TSC2—vascular cancer	0.000989	0.000989	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—TSC2—vascular cancer	0.000971	0.000971	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—TSC2—vascular cancer	0.00095	0.00095	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—TSC2—vascular cancer	0.000933	0.000933	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—TSC2—vascular cancer	0.000922	0.000922	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—TSC2—vascular cancer	0.000919	0.000919	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD34—vascular cancer	0.000894	0.000894	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—TSC2—vascular cancer	0.000885	0.000885	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—TSC2—vascular cancer	0.000883	0.000883	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—WWTR1—vascular cancer	0.000856	0.000856	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—HBA1—vascular cancer	0.000839	0.000839	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—TSC2—vascular cancer	0.000837	0.000837	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—TSC2—vascular cancer	0.000811	0.000811	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—TSC2—vascular cancer	0.000807	0.000807	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD34—vascular cancer	0.000791	0.000791	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—TSC2—vascular cancer	0.000779	0.000779	CbGpPWpGaD
Ponatinib—FGFR3—Disease—TSC2—vascular cancer	0.000773	0.000773	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—WWTR1—vascular cancer	0.000757	0.000757	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TSC2—vascular cancer	0.000732	0.000732	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—WWTR1—vascular cancer	0.00071	0.00071	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—TSC2—vascular cancer	0.000665	0.000665	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—TSC2—vascular cancer	0.000638	0.000638	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—WWTR1—vascular cancer	0.000615	0.000615	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—TSC2—vascular cancer	0.000588	0.000588	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—TSC2—vascular cancer	0.000576	0.000576	CbGpPWpGaD
Ponatinib—KIT—Immune System—TSC2—vascular cancer	0.000566	0.000566	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—TSC2—vascular cancer	0.000565	0.000565	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—HBA1—vascular cancer	0.000555	0.000555	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TSC2—vascular cancer	0.000541	0.000541	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—TSC2—vascular cancer	0.000537	0.000537	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—WWTR1—vascular cancer	0.000536	0.000536	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—TSC2—vascular cancer	0.000535	0.000535	CbGpPWpGaD
Ponatinib—FGFR2—Disease—TSC2—vascular cancer	0.000532	0.000532	CbGpPWpGaD
Ponatinib—KIT—Disease—TSC2—vascular cancer	0.000522	0.000522	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—WWTR1—vascular cancer	0.000505	0.000505	CbGpPWpGaD
Ponatinib—FGFR1—Disease—TSC2—vascular cancer	0.000496	0.000496	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—TSC2—vascular cancer	0.000494	0.000494	CbGpPWpGaD
Ponatinib—LYN—Immune System—TSC2—vascular cancer	0.000472	0.000472	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TSC2—vascular cancer	0.000472	0.000472	CbGpPWpGaD
Ponatinib—ABL1—Immune System—TSC2—vascular cancer	0.00047	0.00047	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—HBA1—vascular cancer	0.000397	0.000397	CbGpPWpGaD
Ponatinib—LCK—Immune System—TSC2—vascular cancer	0.000387	0.000387	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TSC2—vascular cancer	0.000372	0.000372	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TSC2—vascular cancer	0.000366	0.000366	CbGpPWpGaD
Ponatinib—LCK—Disease—TSC2—vascular cancer	0.000357	0.000357	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TSC2—vascular cancer	0.000347	0.000347	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TSC2—vascular cancer	0.000346	0.000346	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—HBA1—vascular cancer	0.000344	0.000344	CbGpPWpGaD
Ponatinib—SRC—Immune System—TSC2—vascular cancer	0.000343	0.000343	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—WWTR1—vascular cancer	0.00033	0.00033	CbGpPWpGaD
Ponatinib—SRC—Disease—TSC2—vascular cancer	0.000316	0.000316	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TSC2—vascular cancer	0.000305	0.000305	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HBA1—vascular cancer	0.0003	0.0003	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HBA1—vascular cancer	0.000283	0.000283	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TSC2—vascular cancer	0.00025	0.00025	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TSC2—vascular cancer	0.000222	0.000222	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HBA1—vascular cancer	0.000185	0.000185	CbGpPWpGaD
